Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2016-10-12 Major Shareholding Noti…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
FMR TP _12Oct2016 NL.pdf
Major Shareholding Notification Classification · 98% confidence The document is titled "Transparantieverklaring – FMR LLC bereikt 10% drempel" (Transparency Declaration – FMR LLC reaches 10% threshold) and explicitly states that Galapagos NV received a notification of a significant shareholding from FMR LLC, detailing the percentage (10%) and the number of voting rights acquired, referencing Belgian transparency legislation. This directly corresponds to the definition of a Major Shareholding Notification, which involves reporting changes in significant share ownership levels crossing thresholds.
2016-10-12 Dutch
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV, for the month of September 2016. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. The document references an attached press release (Exhibit 99.1) but does not contain detailed financial statements or substantive financial data itself. The length is only 1756 characters, indicating it is a brief report or announcement rather than a full financial report. According to the rules, Form 6-K filings are generally considered Regulatory Filings (RNS) unless they contain full financial reports or detailed management discussion. This document is primarily a regulatory filing announcing the press release and does not contain the full report or financial data. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-10-05 English
MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Press Release" and details a clinical trial update regarding a drug candidate (MOR106) being advanced into patient dosing for atopic dermatitis. It includes scientific updates, collaboration details, and forward-looking statements typical of corporate communications announcing operational milestones. This format strongly suggests an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific operational/clinical update rather than a summary of overall financial performance (which would be ER), and it is a formal announcement, it fits best under the general Regulatory Filings category (RNS) or potentially an Earnings Release if such clinical updates are bundled with quarterly results, but given the focus solely on the drug trial, RNS is a safer general classification for non-standard reports. However, press releases announcing key operational milestones, especially clinical trial progress, are often categorized as Earnings Releases (ER) if they contain material non-public information that impacts future earnings expectations, or sometimes as Regulatory Filings (RNS). Given the structure and content (announcing a key development milestone), it is most closely aligned with the type of material information typically disseminated via an Earnings Release (ER) or a general regulatory announcement (RNS). Since it is not a full financial report (10-K, IR) or a presentation (IP), and it is a formal press release, I will classify it as an Earnings Release (ER) as these often include operational highlights that drive financial expectations, or RNS as a fallback. Given the lack of explicit quarterly financial figures, RNS is the most appropriate general regulatory announcement category for this specific type of press release.
2016-09-29 English
MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis
Legal Proceedings Report Classification · 99% confidence The document is titled as a 'Persbericht' (Press Release) dated September 29, 2016, announcing the start of a Phase 1 clinical trial for a new antibody (MOR106) in patients with atopic dermatitis, following positive results in healthy volunteers. It details the study design, the scientific rationale (targeting IL-17C), and includes standard boilerplate sections about the companies (MorphoSys and Galapagos) and forward-looking statements. This content structure—a timely announcement of a specific corporate/clinical development event—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR) or a transcript (CT), and it is a specific, time-sensitive announcement about clinical progress, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) as it is a press release detailing operational news. Given the options, and that it is a formal announcement of a significant operational milestone (clinical trial initiation/update) rather than a general regulatory disclosure, 'ER' (Earnings Release) is often used broadly for major operational updates, but 'RNS' (Regulatory Filings) is the safest fallback for non-standard, non-financial-statement press releases. However, press releases announcing clinical trial progress are often classified as 'RNS' or sometimes 'ER' if they are issued near earnings dates. Since this is a specific operational update and not a summary of financial results, 'RNS' is the most appropriate general regulatory category for this type of announcement that doesn't fit the other specific operational codes (like DIV, CAP, MANG). I will classify it as RNS as it is a general regulatory announcement/press release.
2016-09-29 English
Successful completion of regulatory consultations to progress filgotinib to Phase 3 in inflammatory bowel disease
Regulatory Filings Classification · 95% confidence The document is dated September 27, 2016, and is titled with a headline announcing the 'Successful completion of discussions with regulatory authorities for Phase 3 with filgotinib in intestinal diseases.' The content details the start of Phase 3 studies (DIVERSITY and SELECTION) for a drug (filgotinib) and mentions collaboration with Gilead. It is a press release format, indicated by the contact information, the 'Over Galapagos' section, and the concluding forward-looking statements section which references filings with the SEC (like Form 20-F, which is typical for 10-K/Annual Reports, but this document itself is not the 10-K). Since it is an announcement about clinical trial progress and regulatory discussions, and not a full financial report (10-K, IR) or a transcript (CT), it best fits the category for general corporate news or regulatory updates. Given the options, it is a specific corporate announcement regarding drug development progress, which is often categorized as a general Regulatory Filing (RNS) if no other specific category fits perfectly. However, it is a detailed update on clinical progress and regulatory milestones, which is a key component of investor relations communications. It is not an Earnings Release (ER), nor a specific financial filing like 10-K or IR. It is a press release announcing significant operational/clinical progress. In the context of the provided definitions, 'Regulatory Filings (RNS)' serves as the best general category for non-standard, time-sensitive corporate announcements that are not explicitly covered elsewhere, especially when they relate to regulatory interactions and clinical trial initiation. It is not a Report Publication Announcement (RPA) because it is the news itself, not an announcement *about* another report being published.
2016-09-28 English
Successful completion of regulatory consultations to progress filgotinib to Phase 3 in inflammatory bowel disease
Regulatory Filings Classification · 95% confidence The document is a press release dated September 27, 2016, announcing the successful completion of regulatory consultations to progress the drug filgotinib into Phase 3 clinical trials for inflammatory bowel disease (Crohn's disease and ulcerative colitis). It details study names (DIVERSITY, SELECTION), dosing, patient recruitment, and collaboration with Gilead. This type of announcement, focusing on clinical trial progression and regulatory milestones, is characteristic of an early-stage corporate update, often released via regulatory channels. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it is a specific, time-sensitive corporate action announcement, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for important, non-standardized corporate news releases that are often filed with exchanges. It is not a proxy statement (DEF 14A), dividend notice (DIV), or management change (MANG). Given the content is a specific operational update rather than a general announcement about a report being published (RPA), RNS is the most appropriate fit.
2016-09-28 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.